Recruiting PHASE2 INTERVENTIONAL 13-arm NCT06330064

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Sponsor: Daiichi Sankyo

Conditions Recurrent or Metastatic Solid Tumors

Interventions Ifinatamab deruxtecan

Updated 19 times since 2024 Last updated: Feb 10, 2026 Started: Apr 10, 2024 Primary completion: Jul 25, 2028 Completion: Jul 25, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Recurrent or Metastatic Solid Tumors, this trial is actively recruiting participants. The trial is conducted by Daiichi Sankyo and has accumulated 19 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

19 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE2
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE2
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE2
Oct 2025 — Dec 2025 [monthly]

Recruiting PHASE2
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE2

▶ Show 14 earlier versions

Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE2
Jul 2025 — Aug 2025 [monthly]

Recruiting PHASE2
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE2
May 2025 — Jun 2025 [monthly]

Recruiting PHASE2
Apr 2025 — May 2025 [monthly]

Recruiting PHASE2
Mar 2025 — Apr 2025 [monthly]

Recruiting PHASE2
Feb 2025 — Mar 2025 [monthly]

Recruiting PHASE2
Dec 2024 — Feb 2025 [monthly]

Recruiting PHASE2
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE2
Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE2
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Apr 2024 — May 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daiichi Sankyo
Merck Sharp & Dohme LLC

Data source: Daiichi Sankyo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amarillo, United States , Amsterdam, Netherlands , Ankara, Turkey (Türkiye) , Barcelona, Spain , Barretos, Brazil , Berlin, Germany , Besançon, France , Blacktown, Australia , Bordeaux, France , Brussels, Belgium and 83 more locations